PERJETA is indicated for use in combination with Herceptin® (trastuzumab) and chemotherapy for the adjuvant treatment of patients with HER2-positive early breast cancer (EBC) at high risk of recurrence.1
Discover how the APHINITY trial evaluated PERJETA + Herceptin-based adjuvant therapy in patients with HER2+ EBC.